You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High Grade Serous Ovarian Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High Grade Serous Ovarian Cancer (HGSOC) Trial (FAPI PET CT)

Not yet recruiting
  • High Grade Serous Ovarian Cancer (HGSOC)
  • FAPI PET CT
  • (no location specified)
Jul 20, 2023

New Prognostic Index for Neoadjuvant Chemotherapy Outcome in

Enrolling by invitation
  • Ovarian Cancer
  • +2 more
  • CRS scoring
  • Routine blood laboratory testing before treatment
  • Guangzhou, Guangdong, China
    The Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Nov 2, 2023

High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial (Sovilnesib)

Not yet recruiting
  • High Grade Serous Adenocarcinoma of Ovary
  • +3 more
  • (no location specified)
Oct 13, 2023

High Grade Serous Ovarian Cancer Trial in Montpellier (Blood sample and tissue sample)

Not yet recruiting
  • High Grade Serous Ovarian Cancer
  • Blood sample and tissue sample
  • Montpellier, France
    NOUGARET Stephanie
Oct 10, 2023

High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Peritoneal High Grade Serous

Recruiting
  • High Grade Fallopian Tube Serous Adenocarcinoma
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Ovarian Cancer Trial in Kelowna, Vancouver, Kingston (Durvalumab, BA3011, BA3021)

Recruiting
  • Ovarian Cancer
  • Kelowna, British Columbia, Canada
  • +4 more
Nov 14, 2022

Ovarian Cancer, High Grade Ovarian Serous Trial in New York (PET/MRI, Contrast enhanced CT)

Active, not recruiting
  • Ovarian Cancer
  • High Grade Ovarian Serous
  • PET/MRI
  • Contrast enhanced CT
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Mar 2, 2022

Pembrolizumab and Anlotinib in Treatment of High-Grade Serous

Completed
  • High-Grade Serous Ovarian Cancer
  • Pembrolizumab combined Anlotinib
  • Qingdao, Shandong, China
    Xiaochun Zhang
Dec 26, 2021

miRNAs in High Grade Serous Ovarian Cancer

Recruiting
  • High Grade Serous Ovarian Cancer
    • Bologna, Bo, Italy
      IRCCS- Azienda Ospedaliera-Universitaria di Bologna
    Dec 3, 2021

    Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)

    Not yet recruiting
    • Endometrioid Cancer
    • +3 more
    • VS-6766 + defactinib
    • Oklahoma City, Oklahoma
      Stephenson Cancer Center
    Aug 19, 2022

    High-grade Serous Ovarian Cancer Trial in Belgium, Spain, United Kingdom (APR-246, Pegylated Liposomal Doxorubicin Hydrochloride

    Completed
    Has Results
    • High-grade Serous Ovarian Cancer
    • APR-246
    • Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
    • Gent, Belgium
    • +11 more
    Jul 19, 2022

    Hyperthermic Intraperitoneal Chemo, Neoadjuvant Chemo Trial in Guangzhou (HIPEC, intravenous chemo)

    Recruiting
    • Hyperthermic Intraperitoneal Chemotherapy
    • Neoadjuvant Chemotherapy
    • HIPEC
    • intravenous chemotherapy
    • Guangzhou, Other (Non U.s.), China
      Sun Yat-sen Memorial Hospital
    Feb 17, 2022

    Ovarian Cancer Trial in Manchester (Olaparib, Cediranib, Platinum-based Chemotherapy)

    Completed
    • Ovarian Cancer
    • Manchester, United Kingdom
      The Christie NHS Foundation Trust
    Feb 4, 2022

    Ovarian Tumors Trial in Worldwide (Tilvestamab)

    Recruiting
    • Ovarian Neoplasms
    • Tilvestamab
    • Seoul, Korea, Republic of
    • +8 more
    Jul 19, 2022

    Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

    Recruiting
    • Fallopian Tube Carcinosarcoma
    • +28 more
    • Pegylated Liposomal Doxorubicin Hydrochloride
    • Peposertib
    • Aurora, Colorado
    • +7 more
    Sep 2, 2022

    Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer Trial (Carboplatin)

    Not yet recruiting
    • Ovarian Cancer
    • +6 more
    • (no location specified)
    Oct 27, 2022

    Ovarian Cancer Trial in Groningen (DCP-001)

    Recruiting
    • Ovarian Cancer
    • DCP-001
    • Groningen, Netherlands
      UMCG
    Nov 25, 2021

    Multi-layer Data to Improve Diagnosis, Predict Therapy

    Recruiting
    • High Grade Ovarian Serous Adenocarcinoma
    • WGS and RNA sequencing
    • +2 more
    • Turku, Finland
      Turku University Hospital
    Apr 26, 2022

    Capturing BRCA1/2 Mutational Status in High Grade Serous Ovarian

    Active, not recruiting
    • Ovarian Cancer
    • BRCA genetic data
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 29, 2021

    Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer Trial in Oklahoma City, Houston (AO-252)

    Recruiting
    • Triple Negative Breast Cancer
    • +2 more
    • Oklahoma City, Oklahoma
    • +1 more
    Nov 13, 2023

    Treatment Efficacy in Patients With Ovarian Cancer

    Not yet recruiting
    • High-grade Serous Ovarian Cancer
    • Circulating Tumor DNA
      • (no location specified)
      Aug 25, 2021

      Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer Trial in Guangzhou (Fluzoparib

      Not yet recruiting
      • Ovarian Cancer
      • +4 more
      • Guangzhou, Guangdong, China
        Sun Yat-sen University Cancer Cetntre
      Sep 25, 2023

      Breast Cancer BRCA1 Carriers: a Pilot Study

      Withdrawn
      • BRCA1 Mutation
      • +2 more
      • Mifepristone 200 MG
      • Prophylactic mastectomy
      • Carmel, Indiana
      • +1 more
      Dec 13, 2022

      Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer Trial in Toronto (Niraparib)

      Not yet recruiting
      • Ovarian Cancer
      • +3 more
      • Toronto, Ontario, Canada
        Sunnybrook Research Institute
      Jul 18, 2023

      Variance of HRD From Paired Ovarian Cancer

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
        • Nanjing, Jiangsu, China
          Xiaoxiang Chen
        Sep 25, 2021